Arrowhead Research Corp Files Investigational New Drug Application for Hepatitis B Treatment

Once the national regulatory review has been conducted and the company receives approval, it will initiate two Phase 2b studies to determine the depth of hepatitis B surface antigen (HBsAg) reduction following ARC-520 injection in combination with entecavir or tenofovir in patients with chronic immune active HBV infection. Read more here:


You may also like...